Apimeds Pharmaceuticals US, Inc
APUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $3 | $410 | $6 | $171 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $10 | $12 | $0 | $1 |
| Total Curr. Assets | $13 | $422 | $6 | $172 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $13 | $422 | $6 | $172 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $37 | $11 |
| Short-Term Debt | $250 | $0 | $260 | $0 |
| Tax Payable | $0 | $0 | $1 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $774 | $123 | $22 | $0 |
| Total Curr. Liab. | $1,024 | $123 | $320 | $11 |
| LT Debt | $347 | $267 | $400 | $400 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $347 | $267 | $400 | $400 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,371 | $390 | $720 | $411 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $79 | $206 | $100 | $100 |
| Retained Earnings | -$4,392 | -$3,002 | -$2,224 | -$1,556 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $2,955 | $2,828 | $1,411 | $1,217 |
| Total Equity | -$1,358 | $32 | -$714 | -$238 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $13 | $422 | $6 | $172 |
| Net Debt | $593 | -$144 | $654 | $229 |